维普期刊资源整合服务平台（V6.5）

40篇 您的检索式：作者名="Lurje G"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage Ⅲ colon cancer显示文摘	Lurje G Zhang W Schultheis AM	2008	Annals of Oncology2008，19，10：	1
2	Circulating tumor cells in gastrointestinal malignancies:current techniques and clinical implications 显示文摘	Lurje G Schiesser M Claudius A	2010	J Oncol2010，2010，39：	1
3	Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associmed with tumor recurrence in stage 1] cohm cancer 显示文摘	Lurje G Hendifar AE Schultheis AM	2009	Pharmacogenet Genomics2009，19，2：	1
4	Molecular responseprediction in mult-imodalitytreatment for adenocarcinoma of the esophagus and esophagogastricjunction显示文摘	Lurje G Lenz HJ	2010	Recent Results Cancer Res2010，182，：	1
5	Stem cells in colon cancer显示文摘	Pohl A Lurje G Kahn M	2008	Clinical Colorectal Cancer2008，7，2：	1
6	Pulymorphisms in interleukin 1 beta and interleukio 1 receptor antagonist associated with tumor recurrence in stage Ⅱ colon cancer显示文摘	Lurje G Zhang W Schultheis AM	2009	Pharmocogenetics and Genomics2009，19，2：	1
7	EGFR signaling and drug discovery显示文摘	LURJE G LEZN H J	2009	Oncology2009，77，6：	1
8	EGFR signaling and drug discovery 显示文摘	Lurje G Lenz HJ	2009	Oncology2009，77，6：	1
9	Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab 显示文摘	Lurje G Nagashima F Zhang W	2008	Clin Cancer Res2008，14，23：	1
10	Polymorphisms and clinical outcome in recurrent ovarian cancer treated with eyclophos- phamide and bevacizumab 显示文摘	Schuhheis AM Lurje G Rhodes KE	2008	Clin Cancer Res2008，14，22：	1
11	EGFR signaling and drug discovery显示文摘	Lurje G Lenz HJ	2009	Oncology2009，77，6：	1
12	ICAM- 1, GRP-78, and NFKB gene polymorphisms and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevaeizumab (FOLFOX/BV or XELOX/BV 显示文摘	Manegold PC E1-Khoueiry AB Lurje G	2008	J Clin Oncol2008，26，15：	1
13	EGFR signaling and drug discovery显示文摘	Lurje G Lenz HJ	2009	Oncology2009，77，6：	1
14	Polymor- phisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab显示文摘	Schultheis AM Lurje G Rhodes KE	2008	Clin Cancer Res2008，14，22：	1
15	Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus显示文摘	Lurje G Leers JM Pohl A		0，，5：	1
16	Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage Ⅲ colon cancer显示文摘	G Lurje W Zhang AM Schultheis	2008	Ann Oncol2008，19，：	1
17	Molecular responseprediction in mult-imodalitytreatment for adenocarcinoma of the esophagus and esophagogastricjunction显示文摘	Lurje G Lenz HJ	2010	Recent Results Cancer Res2010，182，：	1
18	EGFR signaling and drug discovery 显示文摘	Lurje G Lenz HJ	2009	Oncology2009，77，6：	1
19	Molecular response prediction in multi- modality treatment for adenocarcinoma of the esophagus and esophagogastric junction 显示文摘	Lurje G Lenz HJ	2010	Recent Results Cancer Res2010，182，：	1
20	Pharmaeogenomics and- genetics in colorectal cancer 显示文摘	Pohl A Lurje G Manegold PC	2009	Adv Drug Deliv Rev2009，61，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示